A single arm, tolerability and safety phase IV study of fulvestrant(Faslodex® ) as 2nd line and later therapy in postmenopausal women with locally advanced or metastatic breast cancer

Trial Identifier: D6998L00004
Sponsor: AstraZeneca
NCTID:: NCT02447328
Start Date: May 2015
Primary Completion Date: May 2016
Study Completion Date: September 2020
Condition: Other; Breast Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
South Korea Cheongju-si, South Korea, 28644
South Korea Daegu, South Korea, 41404
South Korea Goyang-si, South Korea, 10408
South Korea Seo-Gu, South Korea, 49241
South Korea Seongnam-si, South Korea, 13620
South Korea Seoul, South Korea, 135-710
South Korea Seoul, South Korea, 03722
South Korea Seoul, South Korea, 06591
South Korea Seoul, South Korea, 03080
South Korea Seoul, South Korea, 05505